Medication info

LinaDia Duo Tablet 2.5/850 mg

Prescription medicationTabletOral
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Dongkook Pharmaceutical Co., Ltd.
Appearance
Bright orange, double convex, oval film-coated tablet
Packaging
30 tablets/bottle, 60 tablets/bottle, 100 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 201903156 · Approved 2019.05.15

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug treatment who cannot achieve adequate glycemic control with monotherapy, the initial dose of this medicine is 1 tablet of 2.5/500 mg twice daily. The dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Patients who cannot achieve adequate glycemic control with metformin monotherapy: The initial dose of this medicine should include linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching to this medicine from combination therapy with linagliptin and metformin should start at their current doses of linagliptin and metformin. 4. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea: The initial dose of this medicine should be considered to include linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is coadministered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). 5. Patients who cannot achieve adequate glycemic control with combination therapy of insulin and metformin: The initial dose of this medicine should be considered to include linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is coadministered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with another oral antihyperglycemic agent. Any change in the treatment regimen for type 2 diabetes may result in changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment. Treatment should not be initiated with this medicine because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment due to its metformin component (see Precautions for Use, 2. Patients Who Must Not Receive This Medicine).

Ingredients

Manufacturer
Dongkook Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication helps with blood sugar control for patients with type 2 diabetes through the combination of linagliptin and metformin. It provides additional blood sugar control effects in conjunction with dietary and exercise therapies. This stabilizes blood sugar levels and helps prevent diabetes-related complications. It is used to effectively improve patients' blood sugar management.

How to take

Adult dose

The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug treatment who cannot achieve adequate glycemic control with monotherapy, the initial dose of this medicine is 1 tablet of 2.5/500 mg twice daily. The dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Patients who cannot achieve adequate glycemic control with metformin monotherapy: The initial dose of this medicine should include linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching to this medicine from combination therapy with linagliptin and metformin should start at their current doses of linagliptin and metformin. 4. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea: The initial dose of this medicine should be considered to include linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is coadministered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). 5. Patients who cannot achieve adequate glycemic control with combination therapy of insulin and metformin: The initial dose of this medicine should be considered to include linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is coadministered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with another oral antihyperglycemic agent. Any change in the treatment regimen for type 2 diabetes may result in changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment. Treatment should not be initiated with this medicine because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment due to its metformin component (see Precautions for Use, 2. Patients Who Must Not Receive This Medicine).

Precautions

This medication can cause a rare but serious side effect known as lactic acidosis, so it should not be used in patients with impaired liver or kidney function. Patients who are allergic to any ingredients in this medication, or have type 1 diabetes, diabetic ketoacidosis, severe renal impairment, acute infections, or heart diseases should not be administered this medication. Since there is a risk of hypoglycemia, it is important to closely monitor blood sugar levels when used in combination with insulin or sulfonylureas. Patients with reduced kidney function should have regular kidney function tests and should not take this medication if kidney function becomes severely impaired. This medication should be temporarily discontinued before and after acute surgery or the use of iodinated contrast media, and can be resumed after kidney function has normalized. Caution is advised when using this medication in patients with liver dysfunction or heart failure, or those in acute alcohol intoxication. If symptoms suggestive of acute pancreatitis or bullous skin diseases appear during treatment, the medication should be stopped immediately and the patient should consult a physician. The metformin component can cause vitamin B12 deficiency, so regular monitoring of serum vitamin B12 levels is recommended for long-term treatment. It is safest not to take this medication during pregnancy or if there is a possibility of pregnancy, or while breastfeeding. This medication is not recommended for children under 10 years old, as its safety and efficacy have not been established in this age group. Elderly patients have a higher risk of reduced kidney function, so treatment should start at the minimum dose with regular monitoring of kidney function. There is insufficient research on the effects of this medication on driving or operating machinery, so caution is advised. In case of overdose, gastrointestinal disturbances or lactic acidosis may occur, requiring immediate treatment at a hospital, and hemodialysis may be necessary. When storing, keep out of reach of children, avoid moisture, and do not transfer to a different container.

Side effects

Lactic acidosis, pharyngitis, hypersensitivity, angioedema, urticaria, vitamin B12 deficiency and reduction, hypoglycemia, taste disturbance, cough, decreased appetite, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, oral ulcer formation, abnormal liver function tests, hepatitis, pruritus, erythema, rash, vesicular pemphigoid, severe and debilitating arthralgia, rhabdomyolysis, increased lipase, increased amylase, gastroenteritis, shingles, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, constipation, upper abdominal pain, enterocolitis, intestinal obstruction, gastroenteritis, shingles, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, decreased appetite, dehydration, hyperglycemia, cerebral infarction, speech disturbance, Alzheimer's dementia, chest pain, fever, facial swelling, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot, skin lesions, acute leukemia, basal cell carcinoma, non-small cell lung cancer, malignant pericardial effusion, gastric cancer, rectal cancer, pancreatic cancer, meniscus injury, pneumoconiosis, congestive heart failure, angina pectoris, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage kidney disease, acute cholangitis, acute cholecystitis, cholangitis, dizziness, kidney transplant failure, anxiety, affective disorders, insomnia, depression, contusion, bone contusion, concussion, meniscus injury, bone fracture, hand fracture, pneumoconiosis, laceration, palpitations, dry eye, glaucoma, cataract, eye discomfort, allergic conjunctivitis, polyuria, proteinuria, stress urinary incontinence, hematuria, hypotension, flushing, hepatic steatosis, acute cholangitis, acute cholecystitis, cholangitis, cholelithiasis, hearing loss, erectile dysfunction, goiter, anemia, dizziness, sensory impairment, itching, hypertension, benign prostatic hyperplasia, delirium, nocturia, dermatitis, angina pectoris, acute myocardial infarction, unstable angina, stomatitis, mediastinitis, vitreous hemorrhage, ligament sprain, flank pain, myelodysplastic syndrome, vocal cord polyp, dyspepsia, upper abdominal pain, anal bleeding, cheilitis, dental caries, enteritis, gastritis, stomatitis, increased triglycerides in blood, decreased hemoglobin, increased potassium in blood, increased creatinine in blood, increased creatine phosphokinase in blood, increased ALT, increased AST, male pattern baldness, hyperhidrosis, hair loss, dermatitis, anxiety, insomnia, depression, hypertension, dizziness, benign prostatic hyperplasia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it must be stored in a tightly sealed container. Additionally, it should be stored at room temperature between 1°C and 30°C, avoiding extremes of temperature.

Appearance and packaging

Appearance

Bright orange, double convex, oval film-coated tablet

Package unit

30 tablets/bottle, 60 tablets/bottle, 100 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.